SLC4A4 and posterior cortical atrophy: Long-term Enzalutamide treatment leads to the up-regulation of SLC4A4, which in turn mediates P53 Kla via the NF-κB/STAT3/SLC4A4 axis, ultimately leading to the development of Enzalutamide resistance and progression of PCa [118].